W.H.O. BACKS GLP-1 THERAPIES FOR OBESITY BUT WARNS ABOUT LIMITED ACCESS

The World Health Organisation on Monday issued its first guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term treatment for the condition, which affects more than 1 billion people globally according to the agency.

- Reuters

The guidance comes as demand for the class of drugs known as GLP-1 agonists has surged worldwide, and governments are figuring out how to include the blockbuster therapies into public health systems.

The first conditional recommendation advises use of GLP-1 drugs by adults, except pregnant women, for obesity treatment, while the second suggests pairing these with a healthy diet and physical activity.